Key result
This review outlines the definition, diagnosis, and management of diastolic heart failure, noting that specific treatments are lacking but new targeted agents are emerging.
This review summarizes the definition, diagnosis, management, and prognosis of diastolic heart failure.
HFpEF therapies remain largely symptomatic; emerging RAAS data leave open the need for dedicated RCTs.
INTRODUCTION heart failure is an underestimated pathology. Epidemiological and clinical studies suggest that HF with a preserved fraction will become the more common form of HF which clinicians will encounter. Symptomatic treatment focuses on reduction in pulmonary congestion and the improvement in LV filling. Specific treatment is actually lacking, but encouraging are emerging concerning the use of renin–angiotensin–aldosterone axis blockers, nitric oxide donors, or, very recently, agents specifically targeting actin–myosin cross-bridges. It is generally considered to have a somewhat better prognosis systolic HF, but frequency of hospitalizations is comparable in systolic and diastolic HF. 1 Despite the recognition of its , definition and diagnostic criteria of diastolic dysfunction and diastolic HF remain controversial. AND OBJECTIVES review focus of definition, diagnosis and management of diastolic heart failure with it prognosis. AND METHODS have studied various guidelines, articles, reviews using given keywords, along with our experience in management of heart failure in 2015. The articles and the references were reviewed keeping in mind about the simplified management to the patient.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2016) conducted a review in Diastolic heart failure. This review outlines the definition, diagnosis, and management of diastolic heart failure, noting that specific treatments are lacking but new targeted agents are emerging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: